Umbilical cord tissue testing can detect THC metabolites deposited from roughly the second trimester of pregnancy onward, giving it a lookback window of approximately 20 weeks. The test picks up a specific metabolite called THC-COOH that accumulates in the cord’s tissue over months, which makes it far more revealing than a maternal or neonatal urine screen. How much it captures depends on the timing, frequency, and recency of cannabis use, and the relationship between those factors and test results is more nuanced than a simple yes-or-no.
Where the 20-Week Window Comes From
The umbilical cord begins to form early in pregnancy, but the tissue that labs analyze — particularly the gel-like Wharton’s jelly surrounding the cord’s blood vessels — starts accumulating drug metabolites more meaningfully as fetal circulation matures. Research conducted in Colorado, where recreational marijuana is legal, found that umbilical cord homogenate testing detects marijuana use from the second trimester onward and may be useful for gauging use in late pregnancy.1PubMed Central. Prenatal Marijuana Use by Self-Report and Umbilical Cord Sampling in a State With Marijuana Legalization Every woman in that study who reported using cannabis within the last 30 days before delivery had detectable THC-COOH in her cord specimen.
This means the practical detection window spans from early in the second trimester through the day of birth. That said, someone who used cannabis once or twice around week 14 and stopped may have levels too low to register at delivery. The cord captures cumulative exposure, not a single snapshot, so heavier and more recent use produces higher concentrations and greater likelihood of detection.
What the Lab Actually Tests For
The primary target in cord tissue testing is THC-COOH (11-nor-9-carboxy-THC), the main breakdown product of THC. Studies consistently find it to be the predominant metabolite in cord specimens.2Journal of Analytical Toxicology. Development of a Liquid Chromatography–Tandem Mass spectrometry Method for the Simultaneous Determination of Four Cannabinoids in Umbilical Cord Tissue Some labs also measure THC itself, 11-hydroxy-THC, and cannabinol (CBN). One method detected all four of those cannabinoids in cord tissue, though cannabidiol (CBD) turned up only in meconium and not in cord samples.3Clinical Mass Spectrometry. Detection of in utero Exposure to Cannabis in Paired Umbilical Cord Tissue and Meconium by Liquid Chromatography-Tandem Mass Spectrometry
A separate line of research found that THCCOOH-glucuronide, a conjugated form of the metabolite, was actually the most abundant analyte in cord and placenta samples, even though unconjugated THC-COOH dominated in meconium. The researchers suggested THCCOOH-glucuronide could serve as a reliable biomarker for cannabis exposure when cord tissue is the specimen being tested.4Drug Testing and Analysis. Assessment of biological matrices for the detection of in utero cannabis exposure This matters because a lab that only looks for THC-COOH might miss some cases that a lab testing for the glucuronide form would catch.
Most confirmatory cord tissue testing uses liquid chromatography-tandem mass spectrometry, a technique that can distinguish specific molecules with high precision. Published methods report detecting THC-COOH at concentrations as low as 0.1 to 0.2 ng/g of tissue.2Journal of Analytical Toxicology. Development of a Liquid Chromatography–Tandem Mass spectrometry Method for the Simultaneous Determination of Four Cannabinoids in Umbilical Cord Tissue Another validated method used somewhat higher detection thresholds, in the range of 1 to 10 ng/g depending on the analyte.5PubMed. Detection of in utero cannabis exposure by umbilical cord analysis The variation in lab methods means that the same cord specimen could come back positive at one facility and negative at another, depending on the cutoffs in use.
How Use Patterns Shape the Results
Cord tissue testing does more than give a binary positive-or-negative. The concentration of THC-COOH measured in the cord correlates strongly with how often a mother used cannabis near the end of pregnancy. A study of women delivering at two Colorado hospitals found a correlation coefficient of 0.80 between self-reported frequency of marijuana use at delivery and quantified cord THC-COOH levels.6PubMed Central. Quantification of prenatal marijuana use: evaluation of the correlation between self-report, serum, urine and umbilical cord assays among women delivering at two urban Colorado hospitals In plain terms, daily users had much higher cord concentrations than occasional users, and the test reflected that difference reliably.
Recency plays a role too. In the Colorado cord-sampling study, the proportion of women with detectable THC-COOH increased with more recent self-reported use.1PubMed Central. Prenatal Marijuana Use by Self-Report and Umbilical Cord Sampling in a State With Marijuana Legalization Someone who stopped in the second trimester has lower odds of testing positive at delivery than someone who used through the third trimester, even if both consumed similar total amounts. The body continues metabolizing stored THC after cessation, and the cord’s accumulated load gradually reflects less exposure the longer someone has been abstinent before birth.
How Cord Tissue Compares to Meconium
Meconium — the newborn’s first stool — was long considered the gold standard for detecting prenatal drug exposure. Cord tissue has gradually replaced it in many hospitals, but the two specimens are not interchangeable when it comes to cannabis.
Meconium tends to catch more positive cases and at much higher concentrations. One direct comparison found a THC-COOH positivity rate of 35% in meconium versus 25.3% in cord tissue, with the median meconium concentration 36 times higher (72 ng/g versus 2.0 ng/g in cord).7PubMed Central. Can Umbilical Cord and Meconium Results Be Directly Compared? Analytical Approach Matters A separate study that treated meconium as the reference standard found cord tissue was less sensitive for cannabinoid detection, with overall agreement between the two of about 76%.8PubMed. Comparison of umbilical cord tissue and meconium for the confirmation of in utero drug exposure
Despite that sensitivity gap, a larger study of 627 mother-newborn pairs found that cord and meconium agreed 91.3% of the time for cannabinoid results.4Drug Testing and Analysis. Assessment of biological matrices for the detection of in utero cannabis exposure The discrepancy between studies probably reflects differences in which analytes they targeted and how sensitive their methods were. The bottom line is that meconium is the more analytically sensitive matrix for cannabis, but cord tissue still captures the large majority of positive cases.
Why Hospitals Have Moved Toward Cord Testing
If meconium is more sensitive, why are so many hospitals switching to cord tissue? The answer is logistics. The cord is available the moment the baby is delivered. Meconium collection requires waiting for the newborn’s first stool, which sometimes takes hours and can stretch to several days. In some cases, the baby passes meconium in utero before birth, making collection impossible.9PubMed. Testing for fetal exposure to illicit drugs using umbilical cord tissue vs meconium Cord tissue bypasses both problems entirely.
Speed matters for clinical decision-making. Faster turnaround means social services teams and neonatologists can start assessments sooner rather than waiting days for a meconium result. One academic medical center that formally evaluated its switch from meconium to cord testing found no significant difference in the overall detection rate for non-medical drug use between the two specimen types.10PubMed. Evaluating a switch from meconium to umbilical cord tissue for newborn drug testing: A retrospective study at an academic medical center That same study pointed out another advantage: cord tissue collected at delivery avoids potential contamination from medications given to the newborn in the nursery before meconium is passed.
Agreement Across Neonatal Urine, Maternal Urine, and Cord Tissue
Cannabis detection rates look dramatically different depending on which specimen you test. A multi-matrix investigation found THC-COOH in about 57% of maternal urine samples, 15% of cord tissue samples, and only 10% of neonatal urine samples.11Clinical Chemistry. Concordance of Drug Detection Between Neonatal Urine, Maternal Urine, and Umbilical Cord Tissue: A Multi-Matrix Investigation of Prenatal Substance Exposure The agreement between neonatal urine and cord tissue for THC-COOH was poor. Out of 168 cases with results from all three matrices, only 15 were positive across the board. Sixty-seven were positive in maternal urine and cord tissue but negative in neonatal urine.
Each specimen answers a fundamentally different question. Maternal urine reflects what the mother consumed in the last few days. Cord tissue captures months of accumulated fetal exposure. Neonatal urine reflects the tiny fraction that crossed into the fetal kidneys around the time of delivery. A negative neonatal urine test does not mean the baby was unexposed during pregnancy, and a positive maternal urine test does not automatically mean cord tissue will also be positive, since the cord’s threshold and the urine’s threshold operate on completely different timescales and concentration ranges.
When Results Can Mislead
Because THC-COOH concentrations in cord tissue are often very low, results frequently land near the edge of what the lab can reliably measure. The Colorado cord study found that about 22% of cords had THC-COOH above the limit of detection (100 pg/g), but only about 10% also cleared the higher limit of quantification (200 pg/g).1PubMed Central. Prenatal Marijuana Use by Self-Report and Umbilical Cord Sampling in a State With Marijuana Legalization Whether a hospital reports anything above detection or only above quantification can determine whether a result comes back “positive” or “not detected” for the same cord.
A separate concern applies when immunoassay-based screening is used for companion urine specimens. Research has shown that common baby wash and soap products contain chemical surfactants that can trigger false positive results on cannabinoid immunoassays when they come into contact with urine samples.12PubMed. Unexpected interference of baby wash products with a cannabinoid (THC) immunoassay This interference has been documented in urine tests, not in the mass spectrometry methods used for cord tissue. But hospitals that screen newborn urine with an immunoassay alongside cord testing could produce a confusing false positive on the urine side, leading to unnecessary alarm or follow-up.
What Happens After a Positive Result
A positive cord tissue result does not automatically mean a Child Protective Services report will be filed. The specifics vary by state, but clinical and social context plays a role. A universal cord testing program in Appalachia described its process: hospital social services staff are involved when newborns test positive, but multiple factors beyond the test result are considered. Because cord screens are not confirmatory tests collected under chain of custody, the results alone are not treated as sufficient to prompt a CPS call.13The Journal of Applied Laboratory Medicine. Drug Positivity Findings from a Universal Umbilical Cord Tissue Drug Analysis Program in Appalachia
That said, some states have mandatory reporting laws that require healthcare providers to notify authorities whenever a newborn’s drug screen comes back positive, regardless of the substance or circumstances. In those jurisdictions, the clinical nuance described above may be overridden by legal requirements. The tension is especially pronounced with cannabis, which is legal for adult use in a growing number of states. A mother who used marijuana legally before realizing she was pregnant, or who used it in her second trimester and stopped, may still produce a positive cord test at delivery. The test cannot distinguish between a joint last week and one five months ago — it registers that exposure occurred somewhere in that window, without telling you exactly when or how much.
Parents facing this situation should know that the cord test reflects accumulated exposure over months. A positive result is a starting point for a conversation with your care team, not a legal verdict. Asking the hospital which analytes were tested, what the cutoff values were, and whether a confirmatory test was run can help you understand what the result actually means.
Health Outcomes Linked to Prenatal Cannabis Exposure
The clinical motivation behind cord testing extends beyond legal or social reporting. Research suggests that prenatal cannabis exposure is associated with measurable health effects in newborns. One study found that composite neonatal morbidity or death occurred in roughly 14% of neonates born to mothers who used marijuana, compared to about 4.5% among non-users. After adjusting for tobacco, race, and other illicit drug use, marijuana exposure was still associated with about three times the odds of that composite outcome, with infection-related and neurologic complications as the primary drivers.14PubMed Central. Maternal marijuana use, adverse pregnancy outcomes, and neonatal morbidity
The research on long-term outcomes is less settled. Most studies on prenatal cannabis exposure are observational and struggle to separate marijuana from other risk factors like tobacco, alcohol, poverty, and inadequate prenatal care. Still, the short-term association with neonatal morbidity is consistent enough that identifying exposed newborns early — which is what cord testing enables — gives clinical teams the chance to monitor for complications and connect families with appropriate support.